223 articles with NovoCure Ltd.
Results from STELLAR Trial of Tumor Treating Fields with Chemotherapy in Malignant Pleural Mesothelioma Published in The Lancet Oncology
Novocure (NASDAQ: NVCR) today announced that results from the STELLAR trial were published in The Lancet Oncology.
Novocure Announces 27 Presentations at the American Society for Radiation Oncology 2019 Annual Meeting
The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at one of the premier meetings for radiation oncologists
Novocure announced that it will participate in three upcoming investor conferences.
Novocure reported financial results for the three and six months ended June 30, 2019, highlighting a track record of execution, strengthening financial performance and an advancing clinical pipeline.
Novocure announced the U.S Centers for Medicare & Medicaid Services has established a 2019 monthly fee schedule amount for Optune.
Medicare Releases Final Local Coverage Determination Providing Coverage of Optune® for Newly Diagnosed Glioblastoma
Novocure announced the Medicare durable medical equipment Medicare Administrative Contractors have released a final local coverage determination providing coverage of Optune for Medicare beneficiaries with newly diagnosed glioblastoma effective September 1, 2019.
Novocure management will host a conference call and webcast to discuss its financial results for the three months ended June 30, 2019, at 8 a.m. EDT on Thursday, July 25, 2019.
German Institute for Quality and Efficiency in Healthcare Publishes Rapid Report Noting Optune’s Survival Benefit for Patients with Newly Diagnosed Glioblastoma
National reimbursement decision for Optune® in Germany anticipated in 2020
Novocure announced that Bill Doyle, Novocure’s Executive Chairman, will participate in the Jefferies 2019 Global Healthcare Conference on June 4, 2019, in New York City.
Shares of NovoCure are up more than 6% in premarket trading after the company announced it won regulatory approval for its mesothelioma treatment, NovoTTF-100L System.
FDA Approves the NovoTTF-100LTM System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma
Novocure (NASDAQ: NVCR) today announced that the U.S. Food and Drug Administration (FDA) has approved the NovoTTF-100L System in combination with pemetrexed plus platinum-based chemotherapy for the first-line treatment of unresectable, locally advanced or metastatic, malignant pleural mesothelioma (MPM). NovoTTF-100L is a non-invasive, antimitotic cancer treatment that delivers Tumor Treating Fields to the region of the tumor.
Medicare Issues Proposed Local Coverage Determination that Provides Coverage of Optune® for Newly Diagnosed Glioblastoma
Novocure (NASDAQ: NVCR) today announced the Medicare durable medical equipment (DME) Medicare Administrative Contractors (MACs) have issued a proposed local coverage determination (LCD) that provides coverage of Tumor Treating Fields, or Optune, for newly diagnosed glioblastoma (GBM)
Quarterly net revenues of $73.3 million, representing 41 percent growth versus the first quarter 2018 and 5 percent growth versus the fourth quarter 2018
Novocure Announces the International Journal of Radiation Oncology, Biology, Physics Publishes Data Demonstrating Higher Doses of Tumor Treating Fields Improved Survival of Newly Diagnosed Glioblastoma Patients
The study provides a definition for Tumor Treating Fields dose and sets a framework for future work on Tumor Treating Fields dosimetry and treatment planning
Novocure’s mission and values support its overarching patient-forward vision to make a difference in cancer
Inaugural AACR-Novocure Tumor Treating Fields Research Grant Recipients Announced at AACR Annual Meeting 2019
The recipients of the AACR-Novocure Tumor Treating Fields research grants were announced on April 2 at the American Association for Cancer Research Annual Meeting 2019 in Atlanta.
Novocure announced that it will report financial results for the first quarter 2019 on Thursday, May 2, 2019, before the U.S. financial markets open.
INNOVATE-3 will test the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer
3/22/2019Biotech and pharma companies make appointments to strengthen executive teams, with moves at Sanofi, Forma, Orchard, CLSA, Sangamo, and more.
Novocure (NASDAQ: NVCR) today announced the retirement of Dr. Eilon Kirson, Novocure’s Chief Science Officer and Head of Research and Development, effective May 1, 2019.